Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

166 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mitochondrial and cytosolic one-carbon metabolism is a targetable metabolic vulnerability in cisplatin-resistant ovarian cancer.
Wallace-Povirk A, O'Connor C, Dekhne AS, Bao X, Nayeen MJ, Schneider M, Katinas JM, Wong-Roushar J, Kim S, Polin L, Li J, Back JB, Dann CE, Gangjee A, Hou Z, Matherly LH. Wallace-Povirk A, et al. Among authors: gangjee a. Mol Cancer Ther. 2024 Feb 20. doi: 10.1158/1535-7163.MCT-23-0550. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38377173
Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor α and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]pyrimidine Antifolates.
Hou Z, Gattoc L, O'Connor C, Yang S, Wallace-Povirk A, George C, Orr S, Polin L, White K, Kushner J, Morris RT, Gangjee A, Matherly LH. Hou Z, et al. Among authors: gangjee a. Mol Cancer Ther. 2017 May;16(5):819-830. doi: 10.1158/1535-7163.MCT-16-0444. Epub 2017 Jan 30. Mol Cancer Ther. 2017. PMID: 28138029 Free PMC article.
Novel Pyrrolo[3,2-d]pyrimidine Compounds Target Mitochondrial and Cytosolic One-carbon Metabolism with Broad-spectrum Antitumor Efficacy.
Dekhne AS, Shah K, Ducker GS, Katinas JM, Wong-Roushar J, Nayeen MJ, Doshi A, Ning C, Bao X, Frühauf J, Liu J, Wallace-Povirk A, O'Connor C, Dzinic SH, White K, Kushner J, Kim S, Hüttemann M, Polin L, Rabinowitz JD, Li J, Hou Z, Dann CE 3rd, Gangjee A, Matherly LH. Dekhne AS, et al. Among authors: gangjee a. Mol Cancer Ther. 2019 Oct;18(10):1787-1799. doi: 10.1158/1535-7163.MCT-19-0037. Epub 2019 Jul 9. Mol Cancer Ther. 2019. PMID: 31289137 Free PMC article.
Multitargeted 6-Substituted Thieno[2,3-d]pyrimidines as Folate Receptor-Selective Anticancer Agents that Inhibit Cytosolic and Mitochondrial One-Carbon Metabolism.
Tong N, Wong-Roushar J, Wallace-Povirk A, Shah Y, Nyman MC, Katinas JM, Schneider M, O'Connor C, Bao X, Kim S, Li J, Hou Z, Matherly LH, Dann CE 3rd, Gangjee A. Tong N, et al. Among authors: gangjee a. ACS Pharmacol Transl Sci. 2023 Apr 26;6(5):748-770. doi: 10.1021/acsptsci.3c00020. eCollection 2023 May 12. ACS Pharmacol Transl Sci. 2023. PMID: 37200803 Free PMC article.
Therapeutic targeting of a novel 6-substituted pyrrolo [2,3-d]pyrimidine thienoyl antifolate to human solid tumors based on selective uptake by the proton-coupled folate transporter.
Kugel Desmoulin S, Wang L, Hales E, Polin L, White K, Kushner J, Stout M, Hou Z, Cherian C, Gangjee A, Matherly LH. Kugel Desmoulin S, et al. Among authors: gangjee a. Mol Pharmacol. 2011 Dec;80(6):1096-107. doi: 10.1124/mol.111.073833. Epub 2011 Sep 22. Mol Pharmacol. 2011. PMID: 21940787 Free PMC article.
166 results